ClinicalTrials.gg
Status unknownNCT04681053CCOVID-19Updated Feb 24, 2021

Inhaled Ivermectin and COVID-19

A Phase 3 interventional study of Ivermectin Powder in COVID-19, sponsored by Mansoura University. Status unknown at 1 site in Egypt. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-02-24.

Sponsored by Mansoura University · Phase 3, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Dec 2020), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
80
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in COVID-19 by Mansoura University — none open to participants now, none under way, none of them phase 3. COVID-19 · Mansoura University.

Planned enrollment
6th of 10
80 · median 90
Started
2021
with 6 others
Phase 3
5 of 16
none open now
Registered
9th of 16
by date

Among the 16 studies in COVID-19 by Mansoura University, this one is the 6th largest by planned enrollment of the 10 interventional ones that give a count, is one of 7 that started in 2021, is one of 5 in phase 3, and was the 9th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

None of the 16 studies in COVID-19 by Mansoura University is open now. The open studies under COVID-19, anywhere →

Where they have run

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 16 studies in COVID-19 by Mansoura University as a file.
02

Study summary

Coronavirus disease-19 is global healthcare crisis. Till May 20, 2020, there were approximately 4,789,205 cases and 318,789 related mortalities were identified globally. This dramatic situation led to healthcare service collapse in many countries. Each country developed its own action plan depending on healthcare expertise and the available resources. There is no definitive therapy for Coronavirus disease-19 up till now. Many current and investigational drugs are used nowadays. Recent reports suggest a beneficial role of Ivermectin in the management of Coronavirus disease-19. A notice that necessitates further clinical studies.

The aim of this study is to assess the efficacy and safety of the usage of inhaled ivermectin in the management of Coronavirus disease-19.

Read the detailed description

Coronavirus disease-19 (COVID-19) is a pandemic disease which is caused by the SARS-CoV2 virus. It is one of the biggest single-stranded RNA viruses. SARS-CoV2 Viral polyproteins are responsible for viral replication and transcription while its protease enzymes are responsible for polypeptides cleaving and immune system blockage. They are considered to be an important therapeutic target.

Host immunological response against SARS-CoV2 could affect the disease outcome. Patients requiring ICU admission have higher levels of interleukins 6 - 10, tumor necrosis factor α (TNF-α), and fewer CD4+ and CD8+ T cells. The level of cytokines and lymphopenia is associated with pulmonary damage and respiratory distress.

Till now, there is no definitive therapy for COVID-19. Multiple current and investigational drugs are used such as Hydroxychloroquine, lopinavir/ritonavir, and Remdesivir.

Ivermectin: A potent anti-parasitic drug has shown to have an in-vitro antiviral activity against a broad range of viruses. It inhibits the interaction between the human immunodeficiency virus-1 (HIV-1) integrase protein (IN) and the importin (IMP) α/β1. But on the other hand, Ivermectin showed limited efficacy against DENV in phase III clinical trial that was done in Thailand in 2014-2017. Recent Studies proved the In-vitro effect and "subsequently" the possible therapeutic role of Ivermectin in the management of SARS-CoV2.

03

Conditions studied

  • COVID-19

Browse trials for

Keywords

  • COVID
  • Ivermectin
  • Inhalation
  • Antiviral
  • safety
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Both sexes
  • Age above 18
  • Test positive for COVID-19 using Reverse transcription polymerase chain reaction (RT-PCR) prior to the start of study.
  • Willing to participate in the study
  • Mild to moderate severity index according to the WHO criteria

Exclusion criteria

Exclusion Criteria:

  • to the study drug.
  • History of co-morbid conditions such as: uncontrolled hypertension and diabetes, retinal problems and chronic liver and renal disease.
  • Women who are pregnant or breastfeeding.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Active comparator
    Group (A) received both oral and inhaled ivermectin in addition to the standard of care.

    use oral and inhaled ivermectin

    Drug: Ivermectin Powder

  • Active comparator
    B) received oral ivermectin in addition to the standard of care

    receive oral ivermectin

    Drug: Ivermectin Powder

  • Active comparator
    c) received inhaled ivermectin in addition to the standard of care

    received inhaled ivermectin

    Drug: Ivermectin Powder

  • No intervention
    Group (d) received the current standard of care only

    received standard of care only

Interventions

  • DrugIvermectinStudies of IvermectinIvermectin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    - Administration through inhalation (6mg) BID for 3 days

    Also known as: Direct antiviarl agents

06

What researchers measure

Primary outcomes

  1. Rate of virological cure by Rt -PCR for COVID -19 using ivermectin when compared to standard treatment

    All PCR for COVID-19 must be negative

    Time frame: througout the study completion up to one year(for every case must be done after 2 weeks from the start of treatment).

Secondary outcomes

  1. resolution of pneumonia

    The score severity index of pneumonia will be measured before and after receiving treatment by computed tomography (CT)(index from 0-20)increasing the index means increase severity.

    Time frame: througout the study completion up to one year (for every case must be done after 2 weeks from the start of treatment).

07

Study locations

1 of 1 sites recruiting
  • Mansoura Faculty of Medicine
    Mansoura, Dakahlyia 35516, Egypt
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2021; primary completion for Apr 2021, 2 months later.

Of 285 non-industry phase 3 interventional studies under COVID-19, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 19. This study's planned 2 months is below that.

Counting every sponsor, half of 453 studies reached it within 9 months; a quarter within 5 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2020
First posted
Dec 23, 2020
StartEst.
Feb 25, 2021
Primary completionEst.
Apr 30, 2021
CompletionEst.
Dec 31, 2021
Last update
Feb 24, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04681053
Responsible party
Mahmoud Elbendary (Professor of Tropical Medicine and Hepatogastroenterology, Mansoura University) — Principal investigator
First posted
Dec 23, 2020
Start date
Feb 25, 2021 (estimated)
Primary completion
Apr 30, 2021 (estimated)
Completion
Dec 31, 2021 (estimated)
Last update
Feb 24, 2021

Study contacts

Mahmoud El-Bendary, M.D
Contact
mmelbendary@gmail.com
00201002592205
Hatem Elalfy
Contact
elalfy_hatem66@yahoo.com
00201224790518
Mahmoud El-Bendary, M.D
principal investigator · Mansoura University- Faculty of Medicine

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion